The 2018 DNA Damage Response Therapeutics Summit was the first industry-dedicated meeting focused on identifying the next generation of DNA damage response therapeutics, achieving efficacy across a range of contexts, optimizing synthetic lethal screening techniques and exploiting key targets of mechanisms of resistance.

Across 3 content-packed days, the field’s thought leaders from AstraZeneca, Tesaro, Artios, Metabomed, Sierra Oncology and many more shared their insights and lessons learned, collectively enabling the community to:

• Therapeutically Exploit Synthetic Lethal Interactions for Targeted Cancer Therapy

• Optimize the Discovery, Clinical Development & Commercialization of Novel Cancer Therapies Based on the Genetic Concept of Synthetic Lethality

• Leverage Advances in DNA Sequencing and CRISPR-Based Target Discovery to Generate Breakthrough Medicines

Download the 2018 Full Event Guide here.